Michael Anstey

The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA.

Oxford Capital Partners LLP (Oxford Capital Partners) is a venture capital subsidiary of Oxford Capital Partners Holdings Ltd founded in 1999 by Tedd Mott and David Edward Christian Mott. The firm is headquartered in Oxford, the United Kingdom.

Buckman Laboratories SARL wholesales chemicals to the paint industry. The firm markets its products under the brand names such as BUCKMAN, BUFLOC, BULAB, BUSAN, BUSPERSE, and BUTROL. The company was founded on December 21, 2007 and is headquartered in Wasquehal, France.

Congenica Ltd. develops genome-based discovery and diagnostic technologies. It uses Sapientia technology platform, which allows genome scale DNA sequence data to be presented within a clinically actionable diagnostic report. The company was founded by Matthew Hurles, Richard Durbin and Philip Beales in 2013 and is headquartered in Hinxton, the United Kingdom.

Cambridge Innovation Capital Ltd (Cambridge Innovation Capital) is a venture capital firm founded in 2013. The firm is headquartered in Cambridge, United Kingdom.

Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom.

Sense Biodetection Ltd. provides molecular diagnostics research services. It focuses on improving healthcare decisions and processes by developing novel, user-centred, handheld tests in the fields of infections and oncology. The company was founded by Harry John Lamble and Ralph Lamble in 2014 and is headquartered in Abingdon, the United Kingdom.

Proteorex Therapeutics, Inc. develops novel therapeutics. It is discovering small-molecule drugs to treat diseases with the greatest unmet medical need. The firm’s drug discovery platform integrates a novel synthesis design strategy, machine learning, and patient-derived cell-based screening to unlock targets considered undruggable using existing approaches. The company was founded by Aman Iqbal, Kong T. Nguyen, Robert Batey and Michael Anstey and is headquartered in Toronto, Canada.